Business
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of
About this update from Cosmos Health Inc.
[{"type":"text","content":"Record Q1 revenue of $17.9M, up 31% from $13.71 million in Q1 2025, reflecting strength across all core segmentsTotal liabilities decreased by $4.5M, or 9.6%, driven by a substantial reduction in convertible note and credit facility balancesStockholders' equity increased by $1.4M, or 7.6%, with the liabilities-to-assets ratio improving by 370 basis pointsAdjusted EBITDA near breakeven as increased revenue was offset by strategic investments to support global growthRecord momentum continues into Q2 2026 with U.S. expansion actively underwayCHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. (\"Cosmos Health\" or the \"Company\") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today reported financial results for the first quarter ended March 31, 2026.First Quarter 2026 Financial HighlightsIncome StatementCosmos Health delivered the highest Q1 revenue in Company history with continued progress toward adjusted profitability, reflecting broad-based commercial strength - over 75 new pharmacies added at CosmoFarm, growing Sky Premium Life order activity across multiple markets, and expanded contract manufacturing agreements at Cana Laboratories.Revenue was $17.93 million, an increase of 30.7% from $13.71 million in Q1 2025, reflecting strong sales momentum across all core divisions.Adjusted revenue was $18.40 million, up 34.2% year-over-year, reflecting a $470,601 sales discount reversal.Gross profit was $1.38 million in Q1 2026, compared to $2.05 million in Q1 2025, reflecting a revenue mix shift toward wholesale distribution activity at CosmoFarm, compounded by the aforementioned sales discount adjustment.Adjusted gross profit was $1.85 million, reflecting the sales discount reversal applied to revenue.Total operating expenses increased to $3.57 million in Q1 2026, compared to $2.88 million in Q1 2025, reflecting strategic investments in personnel, infrastructure, technology, and AI-driven efficiencies to support global growth initiatives.Net income (loss) was ($2.81 million) in Q1 2026, compared to ($0.82 million) in Q1 2025. The increase is driven principally by $1.15 million of non-cash, non-operational items:$390,350 in non-cash interest on convertible facilities$442,439 in digital asset mark-to-market losses$313,157 in foreign currency translation lossesAdjusted EBITDA was ($229,596) i...